HB111 Alabama 2012 Session

Summary

Primary Sponsor

Jim McClendon

Republican

Session

Regular Session 2012

Title

Health, Hemophilia and bleeding disorders, pharmacy, insurance requirements, von Willebrand's screening, Public Health to administer, Hemophilia Standards of Care Act

Summary

HB111 would create a comprehensive Hemophilia Standards of Care in Alabama, regulate home distribution of clotting products, require insurer coverage for related services, and mandate screening before certain uterine procedures.

What This Bill Does

It sets standards for care of people with bleeding disorders and requires pharmacies that provide home clotting products to meet detailed operational requirements. It also requires health insurers to cover specified services and products for these individuals. It requires physicians to screen for von Willebrand's disease and other bleeding disorders before advising invasive uterine procedures for menorrhagia. It authorizes the Department of Public Health to adopt rules to implement these provisions.

Who It Affects

• People with hemophilia and other bleeding disorders would gain defined standards of care and insurance coverage for treatment and related services.
• Pharmacy providers and home care pharmacies distributing blood clotting products would need to meet several operational standards (on-call pharmacist, rapid shipping, recordkeeping, etc.).
• 340B programs and hemophilia treatment centers would be required to prioritize therapeutic value when supplying clotting products to patients.
• Health insurers would be required to cover specified services and products for affected individuals.
• Physicians would need to order screening for von Willebrand's disease and other bleeding disorders before recommending invasive uterine procedures for menorrhagia.
• The Alabama Department of Public Health would implement rules, oversee compliance, and publish a list of compliant pharmacies; the public Hemophilia Treatment Program would be mostly exempt.

Key Provisions

• Establishes the Hemophilia Standards of Care Act, defining terms such as 340B program, bleeding disorders, and blood clotting products.
• Requires home-distribution pharmacies to meet detailed requirements, including physician-approved substitutions, prioritizing therapeutic value, supplying multiple FDA-approved brands, providing necessary infusion equipment, offering 24/7 pharmacist on call, shipping within 24 hours, and maintaining records and cost information.
• Mandates insurer coverage for services for persons with hemophilia and related disorders, including clotting factors, physician services, and diagnostic laboratory services.
• Requires physicians to obtain medical screening for von Willebrand's disease and other bleeding disorders before advising invasive uterine procedures for menorrhagia.
• Allows the Department of Public Health to adopt rules and to compile a list of compliant full-service home care pharmacies; includes a carve-out for existing public programs like the public Hemophilia Treatment Program.
• Effective date is the first day of the third month after passage and approval.

AI-generated summary using openai/gpt-5-nano on Feb 24, 2026. May contain errors — refer to the official bill text for accuracy.

Subjects

Health